33152854205 17172f8b42 k
33152854205 17172f8b42 k

23andMe Partners With GSK To Develop Novel Medicines

23andMe collaboration expected to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programs

LONDON — GSK and 23andMe today unveiled an exclusive four-year collaboration that will focus on research and development of innovative new medicines and potential cures, using human genetics as the basis for discovery. The collaboration will combine 23andMe’s large-scale genetic resources and advanced data science skills, with the scientific and medical knowledge and commercialization expertise of GSK. The goal of the collaboration is to gather insights and discover novel drug targets driving disease progression and develop therapies for serious unmet medical needs based on those discoveries.

“This collaboration will enable us to deliver on what many customers have been asking for — cures or treatments for diseases.  By leveraging the genetic and phenotypic information provided by consenting 23andMe customers and combining it with GSK’s incredible expertise and resources in drug discovery, we believe we can more quickly make treating and curing diseases a reality,” Anne Wojcicki, CEO and cofounder of 23andMe.

23andMe - Lioness Magazine
23andMe CEO Anne Wojcicki

With over 5 million customers, 23andMe offers those with an interest in genetics the opportunity to learn more about their personal genetic profile. 23andMe customers can also choose to participate in research and contribute their information to a unique and dynamic database, which is now the world’s largest genetic and phenotypic resource.

GSK brings extensive drug discovery and development capabilities across a broad range of diseases and modalities, including small molecule, biopharmaceuticals and cell and gene therapies. It will apply its world-class technologies, including access to additional data sources, in-house target validation and genetics expertise, and utilize its manufacturing, commercial operations and scale to support partner activities across research and development.

Dr. Hal Barron, chief scientific officer and president R&D, GSK, said; “We are excited about this unique collaboration as we know that drug targets with genetic validation have a significantly higher chance of ultimately demonstrating benefit for patients and becoming medicines.  Partnering with 23andMe, an organization whose vision and capabilities are transforming the understanding of how genes influence health, will help to shift our research and development organization to be ‘driven by genetics’, and increase the impact GSK can have on patients.”

According to Pitchbook, 23andMe has authorized the sale of up to $300 million in new shares. “The terms of the deal have not been announced and are subject to change. The company declined to comment. A full $300 million funding could value the company at up to $2.5 billion, per a PitchBook estimate. 23andMe was valued at $1.75 billion with a $250 million funding round last September,” Kate Clark reported.

Check for errors 160x600 1